The FDA issued an alert about dosing errors and overdoses linked to compounded injectable semaglutide products, with some adverse events requiring hospitalization. Errors stemmed from patients self-administering incorrect doses and providers miscalculating doses, often due to confusion over units and unfamiliarity with vial-based injections. The agency urges providers and compounders to counsel patients, supply appropriate syringes, and verify concentrations. Approved semaglutide products like Wegovy, Ozempic, and Rybelsus are not the focus of the alert.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.